Tests orelabrutinib with R-CHOP in newly diagnosed double expression large B-cell lymphoma
Tests orelabrutinib plus R-CHOP chemotherapy in adults newly diagnosed with double expression lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Key facts
- Where
- Jinan and Nanchang, ChinaSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05933967, who can take part
Where in China
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical SciencesJinan, ChinaTaking people
- The First Ailliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shandong Cancer Hospital and Institute
- Trial code
- NCT05933967
- Record updated
- 15 August 2023
- Original description
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.Read full original descriptionShow less
A Phase II, Prospective ,Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
Inclusion: Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma; Age 18-70 years; ECOG performance status 0-2; Ann Arbor stage II-IV; 8.Subjects who in line with the testing standard of the clinical trial laboratory; Life expectancy ≥ 3months.
Exclusion: • systemic lymphoma involved CNS; Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases; uncontrolled infections (including HBV, HCV, HIV/AIDS); Subjects who prepared for transplantation; Pregnancy or active lactation.